The alarming rise in sexually transmitted infections (STIs) across Europe has raised a critical red flag for global public health. The worrying trend is fuelled by the increasing prevalence of antimicrobial-resistant bacteria, which were once thought to be confined to hospital environments but are now freely circulating within communities.
The European Centre for Disease Prevention and Control (ECDC) reports record-high levels of bacterial STIs, with congenital syphilis cases nearly doubling. This surge in drug-resistant gonorrhoea is particularly concerning, with 82 million new cases globally reported in 2020 – a growing number of which are proving difficult to treat due to the erosion of antibiotic effectiveness.
The interconnectedness of our modern world has created an environment conducive to the rapid spread of resistant pathogens. Extensive travel and interaction facilitate the unchecked movement of drug-resistant bacteria across populations, continents, and income levels. This is particularly evident in the spread of extensively drug-resistant gonorrhoea strains, initially detected in Cambodia but now identified as far afield as France and Australia.
One of the most pressing concerns surrounding these resistant strains is their potential to evade treatment. Neisseria gonorrhoeae, the bacteria responsible for gonorrhoea, has developed resistance to multiple antibiotics, with ceftriaxone being the last recommended option. However, an increasing number of cases are now showing resistance even to this.
The spread of antimicrobial-resistant bacteria is not limited to sexual transmission or hospital settings. These pathogens can persist on surfaces and objects, travel easily within cities, and cross borders with remarkable efficiency. As a result, AMR poses a significant threat not just to those infected but also to the broader population, particularly in densely populated urban areas.